New drug trial begins for Tough-to-Treat kidney cancer
NCT ID NCT07300241
Summary
This is the first study in people testing a new oral drug called NEO-811 for advanced kidney cancer that has spread or cannot be removed by surgery. The main goals are to find a safe dose and see how the body handles the drug. It is for patients whose cancer has continued to grow despite standard treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
NEO-811 Dallas Site
RECRUITINGDallas, Texas, 75039, United States
-
NEO-811 Grand Rapids Site
RECRUITINGGrand Rapids, Michigan, 49503, United States
-
NEO-811 Houston Site
RECRUITINGHouston, Texas, 77054, United States
-
NEO-811 Long Island Site
RECRUITINGLake Success, New York, 11042, United States
-
NEO-811 South Carolina Site
RECRUITINGMyrtle Beach, South Carolina, 29572, United States
-
NEO-811 Virginia Site
RECRUITINGFairfax, Virginia, 22031, United States
-
NEO-811-101 NYC Site
RECRUITINGNew York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.